King Luther Capital Management Corp Has $10.45 Million Stake in Revvity Inc. $RVTY
King Luther Capital Management Corp decreased its stake in Revvity Inc. (NYSE:RVTY) by 34.3% in the third quarter, reducing its holdings to 119,216 shares valued at $10.45 million. Despite this, other institutional investors like New York Life Investment Management LLC and Invesco Ltd. increased their positions, with institutional ownership now at 86.65%. Revvity reported strong Q3 earnings, beating analyst estimates, and announced a quarterly dividend and a $1.00 billion share buyback program.
Revvity Inc. (NYSE:RVTY) Given Average Recommendation of "Hold" by Analysts
Analysts have given Revvity Inc. (NYSE:RVTY) an average "Hold" recommendation based on ratings from fourteen brokerages, alongside a mean 12-month price target of $113.67. The company recently exceeded Q4 earnings and revenue expectations and announced a $1.00 billion share repurchase program and a quarterly dividend of $0.07 per share. Institutional investors hold 86.65% of the stock, with shares trading at $97.67, a P/E ratio of 46.96, and a market capitalization of $11.07 billion.
3D Protein Structure Analysis Market Report 2026 Featuring Profiles of Merck, Bruker Corp., Thermo Fisher Scientific, JEOL, Spectris and Other Leading Players
The global 3D protein structure analysis market is projected to grow from $3.4 billion in 2025 to $5.3 billion by 2030, driven by its critical role in drug development, personalized medicine, and biotech research. Key technologies include X-ray crystallography, NMR, and cryo-EM, with North America currently dominating and Asia-Pacific showing rapid growth due to increased R&D and AI integration. Challenges like high equipment costs and a shortage of skilled personnel persist, but technological advancements and strategic investments are propelling market expansion.
$19.8 Billion Cell and Gene Therapy Tools & Reagents Market Outlook, 2030 Featuring Thermo Fisher Scientific, Cytiva (Danaher), Merck, Miltenyi Biotec, Sartorius and More
The global market for cell and gene therapy tools and reagents is projected to reach $19.8 billion by 2030, growing at a CAGR of 10.6% from $12 billion in 2025. This growth is driven by increasing clinical and commercial activities in cell and gene therapies (CGTs), significant R&D investments, and regulatory approvals for novel CGTs. The market report provides comprehensive insights into segmentation by product type, application, and end-user, profiling key players such as Thermo Fisher Scientific, Cytiva (Danaher), Merck, Miltenyi Biotec, and Sartorius.
Is Revvity (RVTY) Now Offering Value After Recent Share Price Weakness
Revvity (RVTY) has experienced recent share price weakness, with declines over the past week, month, and year. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 29.0% at its current price of US$97.74, with an estimated intrinsic value of $137.75 per share. However, its current P/E ratio of 46.19x is higher than Simply Wall St's proprietary "Fair Ratio" of 24.83x, indicating it might be overvalued by that metric.
3 Healthcare Stocks Walking a Fine Line
This article identifies three healthcare stocks—Mettler-Toledo (MTD), Revvity (RVTY), and Royalty Pharma (RPRX)—that are facing challenges despite recent overall positive performance in the healthcare sector. The author highlights concerns such as slow revenue growth, underperforming core businesses, diminishing returns on capital, and valuation issues for these companies. Readers are advised to consider these factors before investing, with suggestions to explore more robust investment opportunities.
First National Bank of Omaha Buys New Position in Revvity Inc. $RVTY
First National Bank of Omaha has acquired a new position in Revvity Inc. (NYSE:RVTY), purchasing 73,384 shares valued at approximately $6.43 million. This comes as Revvity reported strong Q3 earnings, beating analyst estimates with an EPS of $1.70 and revenue of $772.06 million, and announced a $1 billion stock buyback program and a quarterly dividend of $0.07. Several other institutional investors also adjusted their stakes in the company, which continues to draw "Hold" ratings from analysts with a consensus price target of $113.67.
Revvity execs to outline strategy at three March investor events
Revvity (NYSE: RVTY) announced it will present at three investor conferences in March 2026: the Raymond James 47th Annual Institutional Investors Conference, TD Cowen 46th Annual Health Care Conference, and Barclays 28th Annual Global Healthcare Conference. Company executives, including Max Krakowiak (CFO) and Prahlad Singh (CEO), will provide updates on the company's strategic priorities during fireside chats. Live audio webcasts and replays will be available on the company's investor relations website.
Revvity to Present at Upcoming Investor Conferences
Revvity, Inc. (NYSE: RVTY) announced it will present at three upcoming investor conferences in March 2026: the Raymond James 47th Annual Institutional Investors Conference, TD Cowen 46th Annual Health Care Conference, and Barclays 28th Annual Global Healthcare Conference. Company executives, including the CFO and CEO, will provide updates on strategic priorities during fireside chats, with live audio webcasts and replays available on Revvity's investor relations website.
Danaher Nears $10 Billion Acquisition of Masimo
Danaher (DHR) is reportedly close to acquiring Masimo (MASI) for approximately $10 billion, a move that would significantly bolster Danaher's position in the medical technology sector. This acquisition, if finalized, would be Danaher's largest since its $21.4 billion purchase of Cytiva, showcasing its continued investment in biotechnology. Despite a recent decline in Masimo's stock, this deal is expected to provide Danaher with new growth opportunities given the sustained demand for medical devices.
Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter
Revvity (RVTY) has provided a strong financial outlook for 2026, with an adjusted profit forecast of $7.00 to $7.15 per share and revenue expected to be between $3.00 billion and $3.05 billion. These projections are well above current analyst estimates, driven by a robust fourth quarter performance. The life sciences and diagnostics firm's optimistic forecast sent its shares up by 2% in premarket trading.
Discipline and Rules-Based Execution in RVTY Response
This article provides an in-depth analysis of Revvity Inc. (NASDAQ: RVTY), highlighting weak near and mid-term sentiment, but a neutral long-term outlook. It details an exceptional 40:1 risk-reward short setup and offers three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles. The report also includes multi-timeframe signal analysis, identifying support and resistance levels.
Revvity Expands Drug Discovery Tools As Investors Weigh Growth And Valuation
Revvity (NYSE:RVTY) has launched new high-throughput drug discovery platforms at SLAS2026, including advanced screening systems and liquid handlers, to expand its life sciences tool portfolio. This move aims to deepen its presence across the drug discovery workflow, offering more integrated solutions. Investors will monitor the adoption of these new products by pharma and biotech customers, especially given Revvity's recent financial performance and future organic growth forecasts, as they weigh the company's growth potential against its current valuation and competitive landscape.
Revvity Expands Drug Discovery Tools As Investors Weigh Growth And Valuation
Revvity (NYSE:RVTY) has launched new high-throughput drug discovery platforms, including an advanced high-content screening system and a compact liquid handler, aiming to enhance laboratory efficiency. This strategic expansion follows recent financial results showing US$2.86 billion in 2025 sales and US$241.2 million in net income, and comes as the company's stock has seen a significant decline over the past year. Investors are now closely watching how these new offerings will be adopted by the market and contribute to Revvity's projected 2% to 3% organic growth for 2026, considering potential execution risks and competition.
Revvity Expands Drug Discovery Tools As Investors Weigh Growth And Valuation
Revvity (NYSE:RVTY) introduced new discovery platforms at SLAS2026 to enhance high-throughput drug discovery. These products include an advanced high-content screening system, a multimode plate reader, and a compact liquid handler, aiming to provide more integrated solutions. Investors are watching how these launches impact the company's 2026 revenue guidance and its competition with other large tools providers.
Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?
The First Trust Multi Cap Growth AlphaDEX ETF (FAD) provides broad exposure to the All Cap Growth category, using a smart beta strategy based on fundamental characteristics. The ETF has gained approximately 10.63% this year and 18.30% over the past year, with a medium risk profile. Investors should compare it with lower-cost alternatives and conduct thorough research to assess analyst target price validity and inherent risks.
Here's Why Revvity (RVTY) is a Strong Momentum Stock
Revvity (RVTY) is highlighted as a strong momentum stock, receiving a "Hold" rating from Zacks (#3 Rank) with a "B" for its VGM Score and an "A" for its Momentum Style Score. The article explains how Zacks Style Scores (Value, Growth, Momentum, and VGM) complement the Zacks Rank to help investors identify stocks with the highest probability of outperforming the market. RVTY's recent share price increase and upward earnings estimate revisions support its strong momentum profile as a medical stock.
With Revvity, Inc. (NYSE:RVTY) It Looks Like You'll Get What You Pay For
Revvity, Inc. (NYSE:RVTY) has a high price-to-earnings (P/E) ratio of 45.4x, which is significantly above the market average, despite its recent negative earnings growth. Analysts forecast a strong earnings growth of 35% annually for Revvity over the next three years, compared to 12% for the wider market, which explains investor willingness to pay a premium for the stock. While such a high P/E typically signals potential overvaluation, the projected growth suggests that investors are factoring in future performance.
Assessing Revvity (RVTY) Valuation After Recent Share Price Weakness
Revvity's stock has seen recent weakness, declining 13.89% over the past month, but is currently indicated as undervalued by Simply Wall St's models. The company's valuation is driven by an ongoing shift towards higher margin, recurring revenue products and services, with an estimated fair value of US$114.63 against its current US$96.03 share price. However, investors face risks including regulatory changes in China and a high P/E ratio compared to the sector average.
New York Life Investment Management LLC Acquires 11,583 Shares of Revvity Inc. $RVTY
New York Life Investment Management LLC increased its stake in Revvity Inc. by 72.7%, acquiring an additional 11,583 shares, bringing their total ownership to 27,520 shares valued at approximately $2.41 million. This increase contributes to the 86.65% institutional ownership of the company. Recent quarterly results exceeded expectations, with an EPS of $1.70 against an estimated $1.55, and the company announced a $1 billion share buyback program and a $0.07 quarterly dividend.
Revvity Unveils SLAS2026 Platforms As Valuation Gap Attracts Attention
Revvity (NYSE: RVTY) introduced new discovery platforms and technologies at SLAS2026, focusing on high-content screening, plate reading, and laboratory automation to accelerate drug discovery. Despite declining 1, 3, and 5-year returns, the company's shares are trading below estimated fair value, presenting a potential valuation gap. Investors are encouraged to monitor the adoption rates of these new products and their integration into existing lab workflows to assess their impact on Revvity's financial performance.
Down 18.1% in 4 Weeks, Here's Why KORU Medical Systems, Inc. (KRMD) Looks Ripe for a Turnaround
KORU Medical Systems, Inc. (KRMD) stock has declined 18.1% over the past four weeks but appears poised for a turnaround. Its Relative Strength Index (RSI) of 28.55 indicates it is in oversold territory, suggesting a potential trend reversal. Additionally, Wall Street analysts have significantly raised earnings estimates for KRMD, and the stock holds a Zacks Rank #2 (Buy), further supporting a near-term recovery.
Revvity Unveils SLAS2026 Platforms As Valuation Gap Attracts Attention
Revvity (NYSE:RVTY) introduced new discovery platforms and technologies at SLAS2026, focusing on high-content screening, plate reading, and laboratory automation to support faster drug discovery and streamlined workflows. Despite its stock experiencing declines over the past year and several years, the company's valuation is seen as potentially undervalued by 27.4% below estimated fair value. Investors are advised to watch the adoption of these new platforms, their impact on revenue growth, and any adjustments to analyst targets, while also considering the company's relatively high P/E ratio and existing risks.
Revvity Unveils SLAS2026 Platforms As Valuation Gap Attracts Attention
Revvity (NYSE:RVTY) introduced new discovery platforms and technologies at SLAS2026, focusing on high-content screening, plate reading, and laboratory automation. Despite its valuation being 27.4% below estimated fair value and a share price 15% below analyst targets, the company has seen declines in its 1, 3, and 5-year returns. Investors are advised to monitor the adoption of these new platforms, their impact on revenue growth, and any adjustments to analyst forecasts, while also considering Revvity's relatively high P/E ratio and a flagged risk concerning one-off items affecting reported earnings.
Terex Cites ‘Strong Momentum’ in Q4, Full-Year 2025
Terex Corporation announced its Q4 and full-year 2025 results, reporting strong bookings, increased net sales, and improved operating profit. CEO Simon Meester highlighted the successful integration of ESG and the initiation of the merger with REV, expressing confidence in heading into 2026 with considerable momentum. The company navigated various macro and market headwinds to deliver financial results in line with its original guidance.
Revvity Expands Automation Platforms At SLAS2026 As Investors Weigh Long Term Upside
Revvity (NYSE:RVTY) introduced new discovery and automation platforms at SLAS2026, including the Opera Phenix OptIQ high content screening system, EnVision Nexus One plate reader, and AssayMate workstation, alongside collaborations for automated next-gen sequencing. These launches aim to deepen Revvity's focus on high-throughput drug discovery and lab automation for pharmaceutical, biotech, and academic labs. Investors are weighing the potential for recurring revenue from consumables and software against competitive pressures and regulatory risks in the diagnostics and instrument markets.
Revvity Expands Automation Platforms At SLAS2026 As Investors Weigh Long Term Upside
Revvity (NYSE:RVTY) introduced several new high-throughput discovery and automation platforms at SLAS2026, including the Opera Phenix OptIQ system, EnVision Nexus One plate reader, and AssayMate workstation, alongside collaborations in automated next-generation sequencing. These launches aim to address the demand from labs for faster experiments and reduced manual steps, reinforcing Revvity's focus on lab automation and potentially driving recurring revenue. Investors will be monitoring the integration of these systems into customer workflows and their impact on order trends and earnings growth, while considering competitive pressures and regulatory risks.
Revvity Expands Automation Platforms At SLAS2026 As Investors Weigh Long Term Upside
Revvity (NYSE:RVTY) introduced new discovery and automation platforms at SLAS2026, including high content screening systems, plate readers, and workstations, signaling a deeper push into high throughput drug discovery and lab automation. These launches align with the industry's demand for more efficient and reproducible research workflows and could strengthen Revvity's position in genomics and lab automation. Investors will monitor the adoption of these systems, order trends, and potential broader collaborations, while also considering risks such as competition and regulatory pressures.
Revvity boosts momentum at SLAS2026 with full session lineup
Revvity is maintaining its momentum at SLAS2026 with a comprehensive schedule of engaging discussions and numerous sessions planned for day two. The company aims to capitalize on opportunities presented by this leading science and technology conference. Details of specific sessions and topics have been shared via their social media links for attendees.
Optical Preclinical Imaging Market size to hit $982.8 Million
The Optical Preclinical Imaging Market is projected to reach $982.8 million by 2035, growing at a CAGR of 4.7% from its 2025 valuation of $650.1 million. This growth is driven by increasing demand from pharmaceutical and biotechnology companies for researching disease mechanisms, drug efficacy, and therapeutic safety in preclinical models. North America is expected to maintain its market leadership, while Asia Pacific is anticipated to be the fastest-growing region.
Avantor (AVTR) Reports Q4: Everything You Need To Know Ahead Of Earnings
Avantor (AVTR) is set to announce its Q4 earnings results on Wednesday. Analysts expect Avantor's revenue to decrease by 2.9% year-on-year to $1.64 billion, with adjusted earnings around $0.22 per share. The company has a history of missing Wall Street's revenue estimates and its stock has underperformed the research tools & consumables segment recently.
Revvity unveils new high-impact discovery platforms and showcases recent innovations at SLAS2026
Revvity is launching new high-impact discovery platforms and technologies at SLAS2026 to accelerate high-throughput drug discovery. These innovations include the Opera Phenix OptIQ high-content screening system, the EnVision Nexus One multimode plate reader, and the AssayMate workstation, all designed to improve efficiency and data quality in research labs. Kevin Quick, Revvity's vice president of platforms, emphasized that these new offerings integrate automation, trusted assay technologies, and AI-driven imaging to help customers achieve faster results while maintaining high data quality.
Charles River Laboratories (CRL): Buy, Sell, or Hold Post Q3 Earnings?
Despite Charles River Laboratories (CRL) shares outperforming the S&P 500, analysts are cautious about its future. Concerns include declining organic revenue, limited projected revenue growth, and a decrease in Return on Invested Capital (ROIC), suggesting the company's core business is struggling and new investments are not yielding expected returns. While it's not considered a bad business, it doesn't meet the analysts' criteria for a compelling investment opportunity at its current valuation.
Is Revvity (RVTY) Pricing Reflect Its Mixed Returns And Cash Flow Potential
This article analyzes Revvity (RVTY) stock, concluding that its current price of $101.59 suggests it is undervalued by a Discounted Cash Flow (DCF) analysis, which estimates its intrinsic value at $137.95 per share. However, a Price-to-Earnings (P/E) ratio of 48.0x, compared to a "Fair Ratio" of 24.9x, indicates the stock might be overvalued. The article highlights that Revvity's stock performance has been mixed, with a 14.3% decline over the last year, and suggests using "Narratives" for a more comprehensive valuation approach.
Is Revvity (RVTY) Pricing Reflect Its Mixed Returns And Cash Flow Potential
Revvity (RVTY) shows mixed stock performance with a recent decline but a year-to-date gain. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 26.4%, with an estimated intrinsic value of $137.95 per share against a current price of $101.59. However, its P/E ratio of 48.0x is higher than its calculated "Fair Ratio" of 24.9x, indicating it might be overvalued by this metric.
Assessing Revvity (RVTY) Valuation After New SLAS2026 Lab Automation Launches
Revvity (RVTY) recently launched new lab automation tools at SLAS2026, coinciding with its full-year 2025 results and 2026 revenue guidance. Despite some recent stock momentum, Revvity's share price has seen a longer-term decline, leading investors to question if the stock is undervalued given analyst targets and growth expectations. The company's valuation faces scrutiny from its P/E ratio compared to industry averages, alongside potential profit margin challenges.
Assessing Revvity (RVTY) Valuation After New SLAS2026 Lab Automation Launches
Revvity (RVTY) recently introduced new lab automation tools at the SLAS2026 conference, influencing its stock valuation. Despite a recent share price increase, the stock and its P/E ratio are being evaluated against the North American Life Sciences industry average. Analysts suggest Revvity is currently undervalued, with a fair value estimate of US$114.63, driven by expected margin expansion and a shift towards higher-margin offerings.
Truist Financial Corp Decreases Stake in Revvity Inc. $RVTY
Truist Financial Corp reduced its stake in Revvity Inc. by 21.1% in Q3, selling 11,976 shares and retaining 44,764 shares valued at approximately $3.92 million. The reduction comes as Revvity reported strong Q4 earnings, beat revenue estimates, and raised its FY2026 guidance, leading several analysts to increase price targets. Additionally, Revvity's board authorized a $1.0 billion share repurchase program and announced a quarterly dividend.
Revvity unveils new high-impact discovery platforms and showcases recent innovations at SLAS2026
Revvity, Inc. launched new discovery platforms at SLAS2026, including the Opera Phenix OptIQ™ high-content screening system, the EnVision Nexus™ One multimode plate reader, and the AssayMate™ workstation. These innovations aim to accelerate high-throughput drug discovery workflows, spanning sample preparation, screening, advanced imaging, and lab automation. The new technologies are designed to address bottlenecks in phenotypic screening and enhance data quality and automation for various laboratory needs.
3 Unpopular Stocks We Think Twice About
This article highlights three stocks, THOR Industries (THO), Revvity (RVTY), and DigitalBridge (DBRG), that analysts are bearish on. It details the reasons for the negative outlook for each company, citing concerns about sales declines, eroding profitability, and underwhelming returns. The article also suggests alternatives to these "unpopular" stocks by promoting StockStory's "Top 6 Stocks" list for potential growth opportunities.
Revvity (RVTY) Deepens AI And Buybacks Strategy: Is Diagnostics Now Its Core Value Engine?
Revvity (RVTY) reported stronger-than-expected fourth-quarter and full-year 2025 results, with diagnostics showing 7% organic growth. The company is actively pursuing an AI-driven strategy with new tools and acquisitions, alongside significant share repurchases and a dividend. While management highlights transformation and a positive 2026 revenue outlook, challenges remain with lower net income, low returns on equity, and a high P/E ratio compared to peers.
Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026
Revvity, Inc. announced the launch of several new high-impact discovery platforms and technologies at SLAS2026, aimed at accelerating high-throughput drug discovery workflows. These new offerings include the Opera Phenix OptIQ high-content screening system, the EnVision Nexus One multimode plate reader, and the AssayMate workstation. The company emphasizes the integration of automation, trusted assay technologies, and AI-driven imaging to help customers achieve faster results while maintaining data quality.
Danaher Corporation (DHR): A Bull Case Theory
This article summarizes a bullish thesis on Danaher Corporation (DHR), highlighting its long-term compounding machine status, recent earnings beat, strong quality metrics, and robust financial health. Despite some market headwinds, the company's strategic pivots, consistent free cash flow, and exposure to secular growth trends like aging populations position it for sustained shareholder value. The report notes strong hedge fund interest and compares DHR favorably to other investment opportunities, including certain AI stocks.
Analysts Offer Insights on Healthcare Companies: Revvity (RVTY) and Aktis Oncology, Inc. (AKTS)
Analysts from Bank of America Securities and J.P. Morgan have offered insights on healthcare companies Revvity (RVTY) and Aktis Oncology, Inc. (AKTS). Revvity received a Hold rating with a price target of $110.00 from Michael Ryskin, while Aktis Oncology, Inc. was given a Buy rating and a $30.00 price target by Jessica Fye. The consensus ratings for both companies indicate a "Moderate Buy" outlook from analysts.
Cowen & Co. Maintains Hold on Revvity (RVTY) Feb 03, 2026
Cowen & Co. maintained a "Hold" rating on Revvity, Inc. (RVTY) on February 3, 2026, indicating expectations for the stock to perform in line with the market. This unchanged rating suggests a neutral short-term stance, despite TD Cowen separately raising its price target for RVTY to $124 from $120 due to improving 2026 guidance and software catalysts. Investors are advised to monitor organic growth, AI software adoption, and future analyst revisions for potential changes in the stock's outlook.
The Top 5 Analyst Questions From Danaher's Q4 Earnings Call
Danaher (DHR) reported Q4 2025 results that met revenue expectations, driven by strong bioprocessing and diagnostics segments, though academic and government research funding remained soft. This article highlights the top five analyst questions from the earnings call, focusing on drivers for core revenue growth, specifics on SCIEX performance, restructuring efforts, bioprocessing equipment guidance, and the sustainability of life sciences recovery. The company's future catalysts include new diagnostic launches, bioprocessing equipment demand, and stabilization in life sciences and academic funding.
Revvity stock rating reiterated at Overweight by KeyBanc By Investing.com
KeyBanc has reiterated an Overweight rating for Revvity Inc. (NYSE:RVTY) with a price target of $125.00, suggesting a 16.7% upside. Despite the company's fiscal year 2026 organic growth guidance of 2-3% being lower than some peers, KeyBanc highlighted Revvity's strong 4% organic growth in Q4 2025, driven by its diagnostics segment's 7% growth. The firm sees potential for Revvity as market conditions improve and the company accelerates share buybacks, noting its stock trades at a discount to competitors.
Illumina (ILMN) Reports Q4: Everything You Need To Know Ahead Of Earnings
Illumina (ILMN) is set to report its Q4 earnings this Thursday, with analysts predicting a 1.8% year-on-year revenue growth to $1.12 billion and adjusted earnings of $1.25 per share. The company has a strong track record of beating revenue estimates, and analysts have largely reconfirmed their expectations. Investors will be watching closely, especially given recent mixed results from peers in the life sciences tools & services segment.
What To Expect From Mettler-Toledo's (MTD) Q4 Earnings
Mettler-Toledo (MTD) is set to report its Q4 earnings this Thursday afternoon. Analysts expect the company to report revenues of $1.10 billion, a 5.6% year-on-year increase, and adjusted earnings of $12.80 per share. Investors will be watching closely as the company has largely met or exceeded revenue estimates in previous quarters, despite some mixed guidance.
What To Expect From Mettler-Toledo’s (MTD) Q4 Earnings
Mettler-Toledo (MTD) is set to report its Q4 earnings on Thursday afternoon. Analysts anticipate a 5.6% year-on-year revenue growth to $1.10 billion and adjusted earnings of $12.80 per share. Investors will be watching closely after the company's mixed performance last quarter, where it beat revenue estimates but missed guidance expectations.
